[go: up one dir, main page]

WO2009007674A3 - Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires - Google Patents

Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires Download PDF

Info

Publication number
WO2009007674A3
WO2009007674A3 PCT/GB2008/002188 GB2008002188W WO2009007674A3 WO 2009007674 A3 WO2009007674 A3 WO 2009007674A3 GB 2008002188 W GB2008002188 W GB 2008002188W WO 2009007674 A3 WO2009007674 A3 WO 2009007674A3
Authority
WO
WIPO (PCT)
Prior art keywords
seratrodast
ramatroban
atherosclerosis
treatment
mast cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/002188
Other languages
English (en)
Other versions
WO2009007674A2 (fr
Inventor
Johan Raud
Carl-Johan Dalsgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardoz AB
Original Assignee
Cardoz AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz AB filed Critical Cardoz AB
Publication of WO2009007674A2 publication Critical patent/WO2009007674A2/fr
Publication of WO2009007674A3 publication Critical patent/WO2009007674A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des produits d'association comprenant (a) un inhibiteur de mastocyte, ou un sel ou solvate pharmaceutiquement acceptable de celui-ci; et (b) du ramatroban ou du sératrodast, ou un sel ou solvate pharmaceutiquement acceptable de l'un ou l'autre de ces composés. De tels produits d'association ont une utilité particulière dans le traitement de l'athérosclérose et d'états apparentés.
PCT/GB2008/002188 2007-07-11 2008-06-25 Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires Ceased WO2009007674A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92972607P 2007-07-11 2007-07-11
US60/929,726 2007-07-11

Publications (2)

Publication Number Publication Date
WO2009007674A2 WO2009007674A2 (fr) 2009-01-15
WO2009007674A3 true WO2009007674A3 (fr) 2009-03-19

Family

ID=38707246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002188 Ceased WO2009007674A2 (fr) 2007-07-11 2008-06-25 Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires

Country Status (1)

Country Link
WO (1) WO2009007674A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106404930A (zh) * 2016-08-19 2017-02-15 苏州大学附属第二医院 一种测定血浆中5,6‑二氢‑7,8‑二甲基‑4,5‑二氧‑4‑氢‑吡喃喹啉‑2‑羧酸浓度的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009122183A1 (fr) * 2008-04-04 2009-10-08 Cardoz Ab Nouvelle combinaison destinée au traitement de troubles inflammatoires
WO2009122181A1 (fr) * 2008-04-04 2009-10-08 Cardoz Ab Nouvelle combinaison destinée au traitement de troubles inflammatoires
WO2009122182A1 (fr) * 2008-04-04 2009-10-08 Cardoz Ab Nouvelle combinaison destinée au traitement de troubles inflammatoires
EP2303251B1 (fr) * 2008-04-07 2012-05-16 Cardoz AB Nouvelle combinaison pour une utilisation dans le traitement de troubles inflammatoires

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086349A (en) * 1975-07-30 1978-04-25 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma
US4965258A (en) * 1986-02-21 1990-10-23 Bayer Aktiengesellschaft Cycloalkano(1,2-B)indole-sulphonamides, pharmaceutical compositions and use
US6020380A (en) * 1998-11-25 2000-02-01 Tap Holdings Inc. Method of treating chronic obstructive pulmonary disease
US6362214B1 (en) * 1997-12-24 2002-03-26 Bayer Yakuhin, Ltd. Thermodynamically stable form of (R)-3-[[(4-fluorophenyl) sulphonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid (ramatroban)
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086349A (en) * 1975-07-30 1978-04-25 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma
US4965258A (en) * 1986-02-21 1990-10-23 Bayer Aktiengesellschaft Cycloalkano(1,2-B)indole-sulphonamides, pharmaceutical compositions and use
US6362214B1 (en) * 1997-12-24 2002-03-26 Bayer Yakuhin, Ltd. Thermodynamically stable form of (R)-3-[[(4-fluorophenyl) sulphonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid (ramatroban)
US6020380A (en) * 1998-11-25 2000-02-01 Tap Holdings Inc. Method of treating chronic obstructive pulmonary disease
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
DOGNE J-M ET AL: "Recent developments of thromboxane modulators", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 11, no. 11, 2001, pages 1663 - 1675, XP002445841, ISSN: 1354-3776 *
HORIGUCHI T ET AL: "Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 52, no. 10, 2002, pages 764 - 768, XP002998194, ISSN: 0004-4172 *
ISAJI M ET AL: "TRANILAST INHIBITS THE PROLIFERATION, CHEMOTAXIS AND TUBE FORMATIONOF HUMAN MICROVASCULAR ENDOTHELIAL CELLS IN VITRO AND ANGIOGENESIS IN VIVO", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 122, no. 6, November 1997 (1997-11-01), pages 1061 - 1066, XP000997892, ISSN: 0007-1188 *
ISHIZUKA T ET AL: "RAMATROBAN (BAY U 3405): A NOVEL DUAL ANTAGONIST OF TXA2 RECEPTOR AND CRTH2, A NEWLY IDENTIFIED PROSTAGLANDIN D2 RECEPTOR", CARDIOVASCULAR DRUG REVIEWS, NEVA PRESS, BRANFORD, CT, US, vol. 22, no. 2, June 2004 (2004-06-01), pages 71 - 90, XP008078031, ISSN: 0897-5957 *
ISHIZUKA T: "THROMBOXANE A2 RECEPTOR BLOCKADE PREVENTS ATHEROSCLEROTIC PROCESS BY ITS ANTI-INFLAMMATORY EFFECT", VASCULAR DISEASE PREVENTION, BENTHAM SCIENCE PUBLISHERS, GB, vol. 3, no. 2, May 2006 (2006-05-01), pages 143 - 148, XP008078040, ISSN: 1567-2700 *
JONES N L ET AL: "Ketotifen therapy for acute ulcerative colitis in children: A pilot study", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 43, no. 3, 1 March 1998 (1998-03-01), pages 609 - 615, XP008086243, ISSN: 0163-2116 *
MARSHALL J K ET AL: "Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance", CANADIAN JOURNAL OF GASTROENTEROLOGY, MEDICARE PUBL., OAKVILLE, CA, vol. 12, no. 4, 1998, pages 273 - 275, XP008086245, ISSN: 0835-7900 *
MATSUMURA ET AL: "Suppression of atherosclerotic development in watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast", MEDLINE, 23 February 1999 (1999-02-23), XP002953929 *
MINOCHA A ET AL: "Role of ketotifen in pathogenesis of chronic ulcerative colitis", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 104, no. 4 SUPPL, 1993, pages A746, XP008086242, ISSN: 0016-5085 *
NOBUHIDE O ET AL: "Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 56, no. 4, April 2007 (2007-04-01), pages 599 - 600, XP008086231, ISSN: 0017-5749 *
SAIURA A ET AL: "Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 433, no. 2-3, 21 December 2001 (2001-12-21), pages 163 - 168, XP008086230, ISSN: 0014-2999 *
SAMARA E E: "Seratrodast (AA-2414). A novel thromboxane-A-2 receptor antagonist", CARDIOVASCULAR DRUG REVIEWS, NEVA PRESS, BRANFORD, CT, US, vol. 14, no. 3, 1996, pages 272 - 285, XP008082200, ISSN: 0897-5957 *
SHIMIZU T ET AL: "INHIBITORY EFFECTS OF AZELASTINE AND TRANILAST ON LEUKOTRIENE B4 AND LEUKOTRIENE C4, GENERATION BY RAT COLONIC MUCOSA", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 53, no. 5, 1995, pages 355 - 358, XP001042184, ISSN: 0952-3278 *
TEH L G ET AL: "Does the addition of ketotifen to non-steroidal anti-inflammatory drugs confer any additional benefit in rheumatoid arthritis?", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 17, no. 2, 1984, pages 157 - 159, XP008086082, ISSN: 0306-5251 *
YAMADA N ET AL: "MY-1250, a major metabolite of the anti-allergic drug repirinast, induces phosphorylation of a 78-kDa protein in rat mast cells", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 44, no. 6, 25 September 1992 (1992-09-25), pages 1211 - 1213, XP023732179, ISSN: 0006-2952, [retrieved on 19920925] *
ZHANG W ET AL: "Development of new therapeutic effect and mechanism of tranilast", ZHONGGUO XIN YAO YU LINCHUANG ZAZHI - CHINESE JOURNAL OF NEW DRUGS AND CLINICAL REMEDIES, SHANGHAI SHI YIYAO GUANLIJU KE-JI QINGBAO YANJIUSUO ZHONGGUO, CN, vol. 23, no. 11, November 2004 (2004-11-01), pages 795 - 798, XP008086232, ISSN: 1007-7669 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106404930A (zh) * 2016-08-19 2017-02-15 苏州大学附属第二医院 一种测定血浆中5,6‑二氢‑7,8‑二甲基‑4,5‑二氧‑4‑氢‑吡喃喹啉‑2‑羧酸浓度的方法
CN106404930B (zh) * 2016-08-19 2018-08-17 苏州大学附属第二医院 一种测定血浆中5,6-二氢-7,8-二甲基-4,5-二氧-4-氢-吡喃喹啉-2-羧酸浓度的方法

Also Published As

Publication number Publication date
WO2009007674A2 (fr) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2009007673A3 (fr) Nouvelle combinaison pour une utilisation dans le traitement de troubles inflammatoires
WO2009007675A3 (fr) Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
EP2148908B8 (fr) Anti-incrustant à base de polysaccharide
AU2008246443A8 (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
WO2009007674A3 (fr) Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
AU2007337830A8 (en) Benzenesulfonamide derivatives as HIV protease inhibitors
WO2009007679A3 (fr) Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
MX2009006507A (es) Nueva combinacion para usarse en el tratamiento de trastornos inflamatorios.
IL201168A0 (en) New combination for use in the treatment of inflammatory disorders
WO2009007680A3 (fr) Nouvelle combinaison destinée à être utilisée dans le traitement de troubles inflammatoires
AU2004202621A1 (en) Water saver adaptor
EP1794107B8 (fr) Nitrophénols sulfonés en tant qu'inhibiteurs de la polymérisation
AU2005901593A0 (en) Marine Growth Inhibitor
HK1117517A (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
AU2006903310A0 (en) Notebook computer stand
HK1139146A (en) Heterocyclic compounds and use thereof as erk inhibitors
AU2006905290A0 (en) Fast minkowski hull operations
AU2006906611A0 (en) Portable computer
HK1136281A (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
AU2005905018A0 (en) Liquid handling equipment
AU2006904441A0 (en) Wine preservation
HK1127557A (en) Cox-2 inhibitor
AU2005903118A0 (en) Storage vessels
AU2007904269A0 (en) Notebook Computer Stand
AU2007904416A0 (en) Notebook Computer Stand

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08762494

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08762494

Country of ref document: EP

Kind code of ref document: A2